BioCentury
ARTICLE | Clinical News

Zolyd: Ph II/III ZEUS data

April 7, 2017 4:44 AM UTC

The double-blind, international Phase II/III ZEUS trial in 465 patients showed that thrice-daily 6 g IV Zolyd met the primary endpoint of non-inferiority to thrice-daily 4.5 g piperacillin/tazobactam ...

BCIQ Company Profiles

Zavante Therapeutics Inc.